Download PDF
J Neurol Surg A Cent Eur Neurosurg
DOI: 10.1055/a-2312-9813
Original Article

Analysis of KLRB1-Mediated Immunosuppressive Regulation in Adamantinomatous Craniopharyngioma

Wei Wei 
1   Department of Neurosurgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
,
Tao Hong
1   Department of Neurosurgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China
› Author Affiliations Funding This project was funded by the Ganpo555 Engineering Excellence of the Jiangxi Science and Technology Department (Grant/Award number: 2013) and the National Natural Science Foundation of China (Grant/Award number: 82060246).
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Adamantinomatous craniopharyngioma (ACP) is the most common type of craniopharyngioma (CP). Under the current surgery and/or radiotherapy strategies, the survival rate is high, but the long-term quality of life is poor because of the relationship between the hypothalamic–pituitary axis and the tumor. Many studies had shown that endocrine deficiencies caused by craniopharyngiomas of the hypothalamic–pituitary axis persist throughout almost the entire life of the patients after surgery, requiring them to receive hormone replacement therapy. Thus, we need to explore new treatments to improve the prognosis of patients. In recent years, there are more and more studies on the immunotherapy of various tumors. However, due to the rarity of the disease, immunotherapy for ACP is rarely researched. The discovery of the tumor immune-suppressive checkpoint KLRB1 (killer cell lectinlike receptor B1), which encodes CD161, may provide a novel target for the treatment of ACP.

Methods Data analysis of retrospective RNA sequencing was conducted in a cohort of 51 pediatric samples in the GSE94349 dataset, and the results were well validated in the GSE68015 dataset including 31 pediatric samples. We used R language as the main tool for statistical analysis and graphical work.

Results Our research showed that KLRB1 was enriched in ACP. Additionally, the expression of KLRB1 was positively related to immune functions and most inflammatory responses of ACP. We found that most of the T lineage–related immune responses were positively correlated with KLRB1 expression, and KLRB1 played an important role in the activation of inflammatory processes.

Conclusions KLRB1 is a promising target for immunotherapeutic strategies.

Keywords

KLRB1 (CD161) - craniopharyngioma - immunotherapy - inflammatory activation - immune response

Authors' Contributions

T.H. designed the project, while W.W. performed the bioinformatics and statistical analyses, and completed the manuscript. All the authors reviewed and approved the submitted article.




Publication History

Received: 13 September 2023

Accepted: 22 April 2024

Accepted Manuscript online:
24 April 2024

Article published online:
03 July 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Müller HL. Craniopharyngioma. Handb Clin Neurol 2014; 124: 235-253
    CrossrefPubMedSearch in Google Scholar
  • 2 Nielsen EH, Feldt-Rasmussen U, Poulsgaard L. et al. Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults. J Neurooncol 2011; 104 (03) 755-763
    CrossrefPubMedSearch in Google Scholar
  • 3 Zacharia BE, Bruce SS, Goldstein H, Malone HR, Neugut AI, Bruce JN. Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results program. Neuro-oncol 2012; 14 (08) 1070-1078
    CrossrefPubMedSearch in Google Scholar
  • 4 Müller HL, Merchant TE, Warmuth-Metz M, Martinez-Barbera JP, Puget S. Craniopharyngioma. Nat Rev Dis Primers 2019; 5 (01) 75
    CrossrefPubMedSearch in Google Scholar
  • 5 Fujio S, Hanada T, Yonenaga M. et al. Surgical aspects in craniopharyngioma treatment. Innov Surg Sci 2020; 6 (01) 25-33
    PubMedSearch in Google Scholar
  • 6 Adeberg S, Harrabi SB, Bougatf N. et al. Dosimetric comparison of proton radiation therapy, volumetric modulated arc therapy, and three-dimensional conformal radiotherapy based on intracranial tumor location. Cancers (Basel) 2018; 10 (11) 401
    CrossrefPubMedSearch in Google Scholar
  • 7 Lucia K, Vajkoczy P, Kaul D, Strasburger CJ, Onken J. Health-related quality of life in adult patients with craniopharyngioma. World Neurosurg 2021; 154: e46-e53
    CrossrefPubMedSearch in Google Scholar
  • 8 Hoffmann A, Warmth-Metz M, Gebhardt U. et al. Childhood craniopharyngioma: changes of treatment strategies in the trials KRANIOPHARYNGEOM 2000/2007. Klin Padiatr 2014; 226 (03) 161-168
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Calvanese F, Jacquesson T, Manet R. et al. Neoadjuvant B-RAF and MEK inhibitor targeted therapy for adult papillary craniopharyngiomas: a new treatment paradigm. Front Endocrinol (Lausanne) 2022; 13: 882381
    CrossrefPubMedSearch in Google Scholar
  • 10 Mathewson ND, Ashenberg O, Tirosh I. et al. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell 2021; 184 (05) 1281-1298.e26
    CrossrefPubMedSearch in Google Scholar
  • 11 Ye W, Luo C, Li C, Liu Z, Liu F. CD161, a promising immune checkpoint, correlates with patient prognosis: a pan-cancer analysis. J Cancer 2021; 12 (21) 6588-6599
    CrossrefPubMedSearch in Google Scholar
  • 12 Zhou X, Du J, Liu C. et al. A pan-cancer analysis of CD161, a potential new immune checkpoint. Front Immunol 2021; 12: 688215
    CrossrefPubMedSearch in Google Scholar
  • 13 Donson AM, Apps J, Griesinger AM. et al; Advancing Treatment for Pediatric Craniopharyngioma Consortium. Molecular analyses reveal inflammatory mediators in the solid component and cyst fluid of human adamantinomatous craniopharyngioma. J Neuropathol Exp Neurol 2017; 76 (09) 779-788
    CrossrefPubMedSearch in Google Scholar
  • 14 Gump JM, Donson AM, Birks DK. et al. Identification of targets for rational pharmacological therapy in childhood craniopharyngioma. Acta Neuropathol Commun 2015; 3: 30
    CrossrefPubMedSearch in Google Scholar
  • 15 Rody A, Holtrich U, Pusztai L. et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009; 11 (02) R15
    CrossrefPubMedSearch in Google Scholar
  • 16 Wang Z, Zhang C, Liu X. et al. Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. OncoImmunology 2016; 5 (11) e1196310
    CrossrefPubMedSearch in Google Scholar
  • 17 Müller HL. Childhood craniopharyngioma. Pituitary 2013; 16 (01) 56-67
    CrossrefPubMedSearch in Google Scholar
  • 18 Yaxian D, Chunmei Y, Juanyu X, Lei W, Jian G, Chengsong Z. An analysis of clinical characteristics and postoperative complications in children craniopharyngioma. Childs Nerv Syst 2021; 37 (10) 3033-3040
    CrossrefPubMedSearch in Google Scholar
  • 19 Pettorini BL, Inzitari R, Massimi L. et al. The role of inflammation in the genesis of the cystic component of craniopharyngiomas. Childs Nerv Syst 2010; 26 (12) 1779-1784
    CrossrefPubMedSearch in Google Scholar
  • 20 Whelan R, Prince E, Gilani A, Hankinson T. The inflammatory milieu of adamantinomatous craniopharyngioma and its implications for treatment. J Clin Med 2020; 9 (02) 519
    CrossrefPubMedSearch in Google Scholar
  • 21 Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001; 357 (9255) 539-545
    CrossrefPubMedSearch in Google Scholar
  • 22 Zhou J, Zhang C, Pan J, Chen L, Qi ST. Interleukin–6 induces an epithelial–mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration. Mol Med Rep 2017; 15 (06) 4123-4131
    CrossrefPubMedSearch in Google Scholar
  • 23 Martinez-Barbera JP, Andoniadou CL. Concise review: paracrine role of stem cells in pituitary tumors: a focus on adamantinomatous craniopharyngioma. Stem Cells 2016; 34 (02) 268-276
    CrossrefPubMedSearch in Google Scholar